Human Papillomavirus Vaccine Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2027

6.3%
CAGR (2022-2027)
3.28 USD Bn.
Market Size
313
Report Pages
160
Market Tables

Overview

Human Papillomavirus Vaccine Market size is expected to grow at 6.30 % throughout the forecast period, reaching nearly US$ 4.73 Bn. by 2027.

Human papillomavirus vaccine Market
To know about the Research Methodology :- Request Free Sample Report

HPV vaccines are used against viruses to protect human papillomaviruses. Human papilloma viruses (HPV) is a group of more than 200 viruses of which, 40 and more are spread through direct sexual interaction. There are two HPV cause genital warts, and more than dozen HPV types can cause certain types of cancer such as penile, vulvar, cervical, anal, oropharyngeal, and vaginal. HPV vaccines types are licensed for use in the United States such as Gardasil, Gardasil9, and Cervarix. All three vaccines prevent infection from HPV types 16 and 18 viruses, these two high risk viruses responsible for cause about 70% of cervical cancers and even higher percentage of particular type of other HPV-caused cancers. HPV types 6 and 11 are prevented by using Gardasil vaccine, which is responsible to cause 90% of genital warts. Gardasil 9 prevents infection with the same four HPV types plus five additional (31, 33, 45, 52, and 58) cancer-causing types that collected account for 10 to 20% of cervical cancers.

Human papillomavirus vaccine Market Drivers and Restrains

Increasing rates of anal cancer and cervical cancer is expected to increase demand for human papillomavirus vaccine during the forecast period. Growing burden of human papillomavirus infections in emerging economies like India and China is likely to boost the human papillomavirus vaccine market in Asia Pacific. The Centers for Disease Control and Prevention (CDC) states that, human papillomavirus is the most common sexually transmitted infections (STI) in the United States. Overall, 70% of vulvar cancers, 60% of penile cancers and vaginal cancers, and 90% of anal and cervical cancers are caused because of infection of human papillomavirus. CDC also states that about xx million people are diseased by human papillomavirus every year in the United States. According to the Cancer Council Australia, nearly every schools in Australia have chosen to contribute in the National Human Papillomavirus Vaccination Program. In Australia more than xx million doses of vaccines have been directed to girls and young women. This start resulted in approximately 85% decrease in genital warts among heterosexual women and men under the age of 21 years. Approximately 50% reduction in high grade cervical abnormalities in Victorian girls under the age of 18 years.

Manufacturers in the Human papillomavirus vaccine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
In terms of valence type, market is segmented into Bivalent, Quadrivalent and Nonavalent. On the basis of indication type, market is segmented into Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts and others. In recent studies, the sub segment cervical cancer dominated the market and it is expected to continue its dominance during the forecast period. Furthermore, anal cancer was the second largest segment in 2021 and is continue its dominance from 2022 to 2027. The American Society of Clinical Oncology (ASCO) stated that nearly xx women will be diagnosed with cervical cancer in the U.S., and about XX will surrender to the disease.

Human papillomavirus vaccine Market Regional Analysis

On the basis of region global market divided into five region such as Asia Pacific, North America, Europe, Latin America, and Middle East Africa. North America and Western Europe are likely to account for a leading share of the global human papillomavirus vaccine market because of the launch of new vaccines by Major Players in these regions. Growing burden of human papillomavirus infections in emerging economies like India and China is likely to boost the human papillomavirus vaccine market in Asia Pacific. The major key player GlaxoSmithKline plc., received approval for Cervarix in July 2017, which is the product of China (FDA). This is expected to drive the human papillomavirus vaccine market in the Asia Pacific region.

The objective of the report is to present comprehensive analysis of Human papillomavirus vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Human papillomavirus vaccine Market dynamics, structure by analyzing the market segments, and project the Global Human papillomavirus vaccine Market size. Clear representation of competitive analysis of key players by Human papillomavirus vaccine Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Human papillomavirus vaccine Market make the report investor’s guide.

Scope of the Human papillomavirus vaccine Market: Inquire before buying

Global Human papillomavirus vaccine Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 3.28 Bn.
Forecast Period 2022 to 2027 CAGR: 6.30% Market Size in 2027: US $ 4.73 Bn.
Segments Covered: by Valence • Bivalent
• Quadrivalent and Nonavalent
by Indication • Cervical Cancer
• Anal Cancer
• Vaginal Cancer
• Penile Cancer
• Vulvar Cancer
• Oropharyngeal Cancer
• Genital Warts
• Others
by Distribution Channel • Physicians
• Wholesalers
• Physician Distributors
• Government Entities
• Public and Private Alliances

Human papillomavirus vaccine Market, by Region

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Human papillomavirus vaccine Market, Major Players

• Astellas Pharma
• CSL
• Emergent BioSolutions
• GlaxoSmithKline
• Johnson and Johnson
• MedImmune
• Merck
• Pfizer
• Sanofi Pasteur
• Serum Institute
• Bavarian Nordic
• CSL Ltd.
• Emergent Biosolutions, Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences
• Inovio Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Novavax, Inc.
• SELLAS Life Sciences Group, Inc.

Frequently Asked Questions:

1. Which region has the largest share in Global Human papillomavirus vaccine Market?
Ans: Asia Pacific region held the highest share in 2021.

2. What is the growth rate of Global Human papillomavirus vaccine Market?
Ans: The Global Human papillomavirus vaccine Market is expected to grow at a CAGR of 6.30% during forecast period 2022-2027.

3. What is scope of the Global Human papillomavirus vaccine market report?
Ans: Global Human papillomavirus vaccine Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Human papillomavirus vaccine market?
Ans: The important key players in the Global Human papillomavirus vaccine Market are – Astellas Pharma, CSL, Emergent BioSolutions, GlaxoSmithKline, Johnson and Johnson, MedImmune, Merck, Pfizer, Sanofi Pasteur, Serum Institute, Bavarian Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, and Inovio Pharmaceuticals

5. What is the study period of this market?
Ans: The Global Human papillomavirus vaccine Market is studied from 2021 to 2027.

Table of Contents

Human papillomavirus vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Human papillomavirus vaccine Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Human papillomavirus vaccine Market Analysis and Forecast 6.1. Human papillomavirus vaccine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Human papillomavirus vaccine Market Analysis and Forecast, by Valence 7.1. Introduction and Definition 7.2. Key Findings 7.3. Human papillomavirus vaccine Market Value Share Analysis, by Valence 7.4. Human papillomavirus vaccine Market Size (US$ Bn) Forecast, by Valence 7.5. Human papillomavirus vaccine Market Analysis, by Valence 7.6. Human papillomavirus vaccine Market Attractiveness Analysis, by Valence 8. Human papillomavirus vaccine Market Analysis and Forecast, by Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. Human papillomavirus vaccine Market Value Share Analysis, by Indication 8.4. Human papillomavirus vaccine Market Size (US$ Bn) Forecast, by Indication 8.5. Human papillomavirus vaccine Market Analysis, by Indication 8.6. Human papillomavirus vaccine Market Attractiveness Analysis, by Indication 9. Human papillomavirus vaccine Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 9.4. Human papillomavirus vaccine Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Human papillomavirus vaccine Market Analysis, by Distribution Channel 9.6. Human papillomavirus vaccine Market Attractiveness Analysis, by Distribution Channel 10. Human papillomavirus vaccine Market Analysis, by Region 10.1. Human papillomavirus vaccine Market Value Share Analysis, by Region 10.2. Human papillomavirus vaccine Market Size (US$ Bn) Forecast, by Region 10.3. Human papillomavirus vaccine Market Attractiveness Analysis, by Region 11. North America Human papillomavirus vaccine Market Analysis 11.1. Key Findings 11.2. North America Human papillomavirus vaccine Market Overview 11.3. North America Human papillomavirus vaccine Market Value Share Analysis, by Valence 11.4. North America Human papillomavirus vaccine Market Forecast, by Valence 11.4.1. Bivalent 11.4.2. Quadrivalent and Nonavalent 11.5. North America Human papillomavirus vaccine Market Value Share Analysis, by Indication 11.6. North America Human papillomavirus vaccine Market Forecast, by Indication 11.6.1. Cervical Cancer 11.6.2. Anal Cancer 11.6.3. Vaginal Cancer 11.6.4. Penile Cancer 11.6.5. Vulvar Cancer 11.6.6. Oropharyngeal Cancer 11.6.7. Genital Warts 11.6.8. Others 11.7. North America Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 11.8. North America Human papillomavirus vaccine Market Forecast, by Distribution Channel 11.8.1. Physicians 11.8.2. Wholesalers 11.8.3. Physician Distributors 11.8.4. Government Entities 11.8.5. Public and Private Alliances 11.9. North America Human papillomavirus vaccine Market Value Share Analysis, by Country 11.10. North America Human papillomavirus vaccine Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Human papillomavirus vaccine Market Analysis, by Country 11.12. U.S. Human papillomavirus vaccine Market Forecast, by Valence 11.12.1. Bivalent 11.12.2. Quadrivalent and Nonavalent 11.13. U.S. Human papillomavirus vaccine Market Forecast, by Indication 11.13.1. Cervical Cancer 11.13.2. Anal Cancer 11.13.3. Vaginal Cancer 11.13.4. Penile Cancer 11.13.5. Vulvar Cancer 11.13.6. Oropharyngeal Cancer 11.13.7. Genital Warts 11.13.8. Others 11.14. U.S. Human papillomavirus vaccine Market Forecast, by Distribution Channel 11.14.1. Physicians 11.14.2. Wholesalers 11.14.3. Physician Distributors 11.14.4. Government Entities 11.14.5. Public and Private Alliances 11.15. Canada Human papillomavirus vaccine Market Forecast, by Valence 11.15.1. Bivalent 11.15.2. Quadrivalent and Nonavalent 11.16. Steel Canada Human papillomavirus vaccine Market Forecast, by Indication 11.16.1. Cervical Cancer 11.16.2. Anal Cancer 11.16.3. Vaginal Cancer 11.16.4. Penile Cancer 11.16.5. Vulvar Cancer 11.16.6. Oropharyngeal Cancer 11.16.7. Genital Warts 11.16.8. Others 11.17. Canada Human papillomavirus vaccine Market Forecast, by Distribution Channel 11.17.1. Physicians 11.17.2. Wholesalers 11.17.3. Physician Distributors 11.17.4. Government Entities 11.17.5. Public and Private Alliances 11.18. North America Human papillomavirus vaccine Market Attractiveness Analysis 11.18.1. By Valence 11.18.2. By Indication 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Human papillomavirus vaccine Market Analysis 12.1. Key Findings 12.2. Europe Human papillomavirus vaccine Market Overview 12.3. Europe Human papillomavirus vaccine Market Value Share Analysis, by Valence 12.4. Europe Human papillomavirus vaccine Market Forecast, by Valence 12.4.1. Bivalent 12.4.2. Quadrivalent and Nonavalent 12.5. Europe Human papillomavirus vaccine Market Value Share Analysis, by Indication 12.6. Europe Human papillomavirus vaccine Market Forecast, by Indication 12.6.1. Cervical Cancer 12.6.2. Anal Cancer 12.6.3. Vaginal Cancer 12.6.4. Penile Cancer 12.6.5. Vulvar Cancer 12.6.6. Oropharyngeal Cancer 12.6.7. Genital Warts 12.6.8. Others 12.7. Europe Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 12.8. Europe Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.8.1. Physicians 12.8.2. Wholesalers 12.8.3. Physician Distributors 12.8.4. Government Entities 12.8.5. Public and Private Alliances 12.9. Europe Human papillomavirus vaccine Market Value Share Analysis, by Country 12.10. Europe Human papillomavirus vaccine Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Human papillomavirus vaccine Market Analysis, by Country 12.12. Germany Human papillomavirus vaccine Market Forecast, by Valence 12.12.1. Bivalent 12.12.2. Quadrivalent and Nonavalent 12.13. Germany Human papillomavirus vaccine Market Forecast, by Indication 12.13.1. Cervical Cancer 12.13.2. Anal Cancer 12.13.3. Vaginal Cancer 12.13.4. Penile Cancer 12.13.5. Vulvar Cancer 12.13.6. Oropharyngeal Cancer 12.13.7. Genital Warts 12.13.8. Others 12.14. Germany Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.14.1. Physicians 12.14.2. Wholesalers 12.14.3. Physician Distributors 12.14.4. Government Entities 12.14.5. Public and Private Alliances 12.15. U.K. Human papillomavirus vaccine Market Forecast, by Valence 12.15.1. Bivalent 12.15.2. Quadrivalent and Nonavalent 12.16. U.K. Human papillomavirus vaccine Market Forecast, by Indication 12.16.1. Cervical Cancer 12.16.2. Anal Cancer 12.16.3. Vaginal Cancer 12.16.4. Penile Cancer 12.16.5. Vulvar Cancer 12.16.6. Oropharyngeal Cancer 12.16.7. Genital Warts 12.16.8. Others 12.17. U.K. Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.17.1. Physicians 12.17.2. Wholesalers 12.17.3. Physician Distributors 12.17.4. Government Entities 12.17.5. Public and Private Alliances 12.18. France Human papillomavirus vaccine Market Forecast, by Valence 12.18.1. Bivalent 12.18.2. Quadrivalent and Nonavalent 12.19. France Human papillomavirus vaccine Market Forecast, by Indication 12.19.1. Cervical Cancer 12.19.2. Anal Cancer 12.19.3. Vaginal Cancer 12.19.4. Penile Cancer 12.19.5. Vulvar Cancer 12.19.6. Oropharyngeal Cancer 12.19.7. Genital Warts 12.19.8. Others 12.20. France Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.20.1. Physicians 12.20.2. Wholesalers 12.20.3. Physician Distributors 12.20.4. Government Entities 12.20.5. Public and Private Alliances 12.21. Italy Human papillomavirus vaccine Market Forecast, by Valence 12.21.1. Bivalent 12.21.2. Quadrivalent and Nonavalent 12.22. Italy Human papillomavirus vaccine Market Forecast, by Indication 12.22.1. Cervical Cancer 12.22.2. Anal Cancer 12.22.3. Vaginal Cancer 12.22.4. Penile Cancer 12.22.5. Vulvar Cancer 12.22.6. Oropharyngeal Cancer 12.22.7. Genital Warts 12.22.8. Others 12.23. Italy Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.23.1. Physicians 12.23.2. Wholesalers 12.23.3. Physician Distributors 12.23.4. Government Entities 12.23.5. Public and Private Alliances 12.24. Spain Human papillomavirus vaccine Market Forecast, by Valence 12.24.1. Bivalent 12.24.2. Quadrivalent and Nonavalent 12.25. Spain Human papillomavirus vaccine Market Forecast, by Indication 12.25.1. Cervical Cancer 12.25.2. Anal Cancer 12.25.3. Vaginal Cancer 12.25.4. Penile Cancer 12.25.5. Vulvar Cancer 12.25.6. Oropharyngeal Cancer 12.25.7. Genital Warts 12.25.8. Others 12.26. Spain Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.26.1. Physicians 12.26.2. Wholesalers 12.26.3. Physician Distributors 12.26.4. Government Entities 12.26.5. Public and Private Alliances 12.27. Rest of Europe Human papillomavirus vaccine Market Forecast, by Valence 12.27.1. Bivalent 12.27.2. Quadrivalent and Nonavalent 12.28. Rest of Europe Human papillomavirus vaccine Market Forecast, by Indication 12.28.1. Cervical Cancer 12.28.2. Anal Cancer 12.28.3. Vaginal Cancer 12.28.4. Penile Cancer 12.28.5. Vulvar Cancer 12.28.6. Oropharyngeal Cancer 12.28.7. Genital Warts 12.28.8. Others 12.29. Rest Of Europe Human papillomavirus vaccine Market Forecast, by Distribution Channel 12.29.1. Physicians 12.29.2. Wholesalers 12.29.3. Physician Distributors 12.29.4. Government Entities 12.29.5. Public and Private Alliances 12.30. Europe Human papillomavirus vaccine Market Attractiveness Analysis 12.30.1. By Valence 12.30.2. By Indication 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Human papillomavirus vaccine Market Analysis 13.1. Key Findings 13.2. Asia Pacific Human papillomavirus vaccine Market Overview 13.3. Asia Pacific Human papillomavirus vaccine Market Value Share Analysis, by Valence 13.4. Asia Pacific Human papillomavirus vaccine Market Forecast, by Valence 13.4.1. Bivalent 13.4.2. Quadrivalent and Nonavalent 13.5. Asia Pacific Human papillomavirus vaccine Market Value Share Analysis, by Indication 13.6. Asia Pacific Human papillomavirus vaccine Market Forecast, by Indication 13.6.1. Cervical Cancer 13.6.2. Anal Cancer 13.6.3. Vaginal Cancer 13.6.4. Penile Cancer 13.6.5. Vulvar Cancer 13.6.6. Oropharyngeal Cancer 13.6.7. Genital Warts 13.6.8. Others 13.7. Asia Pacific Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.8.1. Physicians 13.8.2. Wholesalers 13.8.3. Physician Distributors 13.8.4. Government Entities 13.8.5. Public and Private Alliances 13.9. Asia Pacific Human papillomavirus vaccine Market Value Share Analysis, by Country 13.10. Asia Pacific Human papillomavirus vaccine Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Human papillomavirus vaccine Market Analysis, by Country 13.12. China Human papillomavirus vaccine Market Forecast, by Valence 13.12.1. Bivalent 13.12.2. Quadrivalent and Nonavalent 13.13. China Human papillomavirus vaccine Market Forecast, by Indication 13.13.1. Cervical Cancer 13.13.2. Anal Cancer 13.13.3. Vaginal Cancer 13.13.4. Penile Cancer 13.13.5. Vulvar Cancer 13.13.6. Oropharyngeal Cancer 13.13.7. Genital Warts 13.13.8. Others 13.14. China Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.14.1. Physicians 13.14.2. Wholesalers 13.14.3. Physician Distributors 13.14.4. Government Entities 13.14.5. Public and Private Alliances 13.15. India Human papillomavirus vaccine Market Forecast, by Valence 13.15.1. Bivalent 13.15.2. Quadrivalent and Nonavalent 13.16. India Human papillomavirus vaccine Market Forecast, by Indication 13.16.1. Cervical Cancer 13.16.2. Anal Cancer 13.16.3. Vaginal Cancer 13.16.4. Penile Cancer 13.16.5. Vulvar Cancer 13.16.6. Oropharyngeal Cancer 13.16.7. Genital Warts 13.16.8. Others 13.17. India Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.17.1. Physicians 13.17.2. Wholesalers 13.17.3. Physician Distributors 13.17.4. Government Entities 13.17.5. Public and Private Alliances 13.18. Japan Human papillomavirus vaccine Market Forecast, by Valence 13.18.1. Bivalent 13.18.2. Quadrivalent and Nonavalent 13.19. Japan Human papillomavirus vaccine Market Forecast, by Indication 13.19.1. Cervical Cancer 13.19.2. Anal Cancer 13.19.3. Vaginal Cancer 13.19.4. Penile Cancer 13.19.5. Vulvar Cancer 13.19.6. Oropharyngeal Cancer 13.19.7. Genital Warts 13.19.8. Others 13.20. Japan Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.20.1. Physicians 13.20.2. Wholesalers 13.20.3. Physician Distributors 13.20.4. Government Entities 13.20.5. Public and Private Alliances 13.21. ASEAN Human papillomavirus vaccine Market Forecast, by Valence 13.21.1. Bivalent 13.21.2. Quadrivalent and Nonavalent 13.22. ASEAN Human papillomavirus vaccine Market Forecast, by Indication 13.22.1. Cervical Cancer 13.22.2. Anal Cancer 13.22.3. Vaginal Cancer 13.22.4. Penile Cancer 13.22.5. Vulvar Cancer 13.22.6. Oropharyngeal Cancer 13.22.7. Genital Warts 13.22.8. Others 13.23. ASEAN Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.23.1. Physicians 13.23.2. Wholesalers 13.23.3. Physician Distributors 13.23.4. Government Entities 13.23.5. Public and Private Alliances 13.24. Rest of Asia Pacific Human papillomavirus vaccine Market Forecast, by Valence 13.24.1. Bivalent 13.24.2. Quadrivalent and Nonavalent 13.25. Rest of Asia Pacific Human papillomavirus vaccine Market Forecast, by Indication 13.25.1. Cervical Cancer 13.25.2. Anal Cancer 13.25.3. Vaginal Cancer 13.25.4. Penile Cancer 13.25.5. Vulvar Cancer 13.25.6. Oropharyngeal Cancer 13.25.7. Genital Warts 13.25.8. Others 13.26. Rest of Asia Pacific Human papillomavirus vaccine Market Forecast, by Distribution Channel 13.26.1. Physicians 13.26.2. Wholesalers 13.26.3. Physician Distributors 13.26.4. Government Entities 13.26.5. Public and Private Alliances 13.27. Asia Pacific Human papillomavirus vaccine Market Attractiveness Analysis 13.27.1. By Valence 13.27.2. By Indication 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Human papillomavirus vaccine Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Human papillomavirus vaccine Market Overview 14.3. Middle East & Africa Human papillomavirus vaccine Market Value Share Analysis, by Valence 14.4. Middle East & Africa Human papillomavirus vaccine Market Forecast, by Valence 14.4.1. Bivalent 14.4.2. Quadrivalent and Nonavalent 14.5. Middle East & Africa Human papillomavirus vaccine Market Value Share Analysis, by Indication 14.6. Middle East & Africa Human papillomavirus vaccine Market Forecast, by Indication 14.6.1. Cervical Cancer 14.6.2. Anal Cancer 14.6.3. Vaginal Cancer 14.6.4. Penile Cancer 14.6.5. Vulvar Cancer 14.6.6. Oropharyngeal Cancer 14.6.7. Genital Warts 14.6.8. Others 14.7. Middle East & Africa Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Human papillomavirus vaccine Market Forecast, by Distribution Channel 14.8.1. Physicians 14.8.2. Wholesalers 14.8.3. Physician Distributors 14.8.4. Government Entities 14.8.5. Public and Private Alliances 14.9. Middle East & Africa Human papillomavirus vaccine Market Value Share Analysis, by Country 14.10. Middle East & Africa Human papillomavirus vaccine Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Human papillomavirus vaccine Market Analysis, by Country 14.12. GCC Human papillomavirus vaccine Market Forecast, by Valence 14.12.1. Bivalent 14.12.2. Quadrivalent and Nonavalent 14.13. GCC Human papillomavirus vaccine Market Forecast, by Indication 14.13.1. Cervical Cancer 14.13.2. Anal Cancer 14.13.3. Vaginal Cancer 14.13.4. Penile Cancer 14.13.5. Vulvar Cancer 14.13.6. Oropharyngeal Cancer 14.13.7. Genital Warts 14.13.8. Others 14.14. GCC Human papillomavirus vaccine Market Forecast, by Distribution Channel 14.14.1. Physicians 14.14.2. Wholesalers 14.14.3. Physician Distributors 14.14.4. Government Entities 14.14.5. Public and Private Alliances 14.15. South Africa Human papillomavirus vaccine Market Forecast, by Valence 14.15.1. Bivalent 14.15.2. Quadrivalent and Nonavalent 14.16. South Africa Human papillomavirus vaccine Market Forecast, by Indication 14.16.1. Cervical Cancer 14.16.2. Anal Cancer 14.16.3. Vaginal Cancer 14.16.4. Penile Cancer 14.16.5. Vulvar Cancer 14.16.6. Oropharyngeal Cancer 14.16.7. Genital Warts 14.16.8. Others 14.17. South Africa Human papillomavirus vaccine Market Forecast, by Distribution Channel 14.17.1. Physicians 14.17.2. Wholesalers 14.17.3. Physician Distributors 14.17.4. Government Entities 14.17.5. Public and Private Alliances 14.18. Rest of Middle East & Africa Human papillomavirus vaccine Market Forecast, by Valence 14.18.1. Bivalent 14.18.2. Quadrivalent and Nonavalent 14.19. Rest of Middle East & Africa Human papillomavirus vaccine Market Forecast, by Indication 14.19.1. Cervical Cancer 14.19.2. Anal Cancer 14.19.3. Vaginal Cancer 14.19.4. Penile Cancer 14.19.5. Vulvar Cancer 14.19.6. Oropharyngeal Cancer 14.19.7. Genital Warts 14.19.8. Others 14.20. Rest of Middle East & Africa Human papillomavirus vaccine Market Forecast, by Distribution Channel 14.20.1. Physicians 14.20.2. Wholesalers 14.20.3. Physician Distributors 14.20.4. Government Entities 14.20.5. Public and Private Alliances 14.21. Middle East & Africa Human papillomavirus vaccine Market Attractiveness Analysis 14.21.1. By Valence 14.21.2. By Indication 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Human papillomavirus vaccine Market Analysis 15.1. Key Findings 15.2. South America Human papillomavirus vaccine Market Overview 15.3. South America Human papillomavirus vaccine Market Value Share Analysis, by Valence 15.4. South America Human papillomavirus vaccine Market Forecast, by Valence 15.4.1. Bivalent 15.4.2. Quadrivalent and Nonavalent 15.5. South America Human papillomavirus vaccine Market Value Share Analysis, by Indication 15.6. South America Human papillomavirus vaccine Market Forecast, by Indication 15.6.1. Cervical Cancer 15.6.2. Anal Cancer 15.6.3. Vaginal Cancer 15.6.4. Penile Cancer 15.6.5. Vulvar Cancer 15.6.6. Oropharyngeal Cancer 15.6.7. Genital Warts 15.6.8. Others 15.7. South America Human papillomavirus vaccine Market Value Share Analysis, by Distribution Channel 15.8. South America Human papillomavirus vaccine Market Forecast, by Distribution Channel 15.8.1. Physicians 15.8.2. Wholesalers 15.8.3. Physician Distributors 15.8.4. Government Entities 15.8.5. Public and Private Alliances 15.9. South America Human papillomavirus vaccine Market Value Share Analysis, by Country 15.10. South America Human papillomavirus vaccine Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Human papillomavirus vaccine Market Analysis, by Country 15.12. Brazil Human papillomavirus vaccine Market Forecast, by Valence 15.12.1. Bivalent 15.12.2. Quadrivalent and Nonavalent 15.13. Brazil Human papillomavirus vaccine Market Forecast, by Indication 15.13.1. Cervical Cancer 15.13.2. Anal Cancer 15.13.3. Vaginal Cancer 15.13.4. Penile Cancer 15.13.5. Vulvar Cancer 15.13.6. Oropharyngeal Cancer 15.13.7. Genital Warts 15.13.8. Others 15.14. Brazil Human papillomavirus vaccine Market Forecast, by Distribution Channel 15.14.1. Physicians 15.14.2. Wholesalers 15.14.3. Physician Distributors 15.14.4. Government Entities 15.14.5. Public and Private Alliances 15.15. Mexico Human papillomavirus vaccine Market Forecast, by Valence 15.15.1. Bivalent 15.15.2. Quadrivalent and Nonavalent 15.16. Mexico Human papillomavirus vaccine Market Forecast, by Indication 15.16.1. Cervical Cancer 15.16.2. Anal Cancer 15.16.3. Vaginal Cancer 15.16.4. Penile Cancer 15.16.5. Vulvar Cancer 15.16.6. Oropharyngeal Cancer 15.16.7. Genital Warts 15.16.8. Others 15.17. Mexico Human papillomavirus vaccine Market Forecast, by Distribution Channel 15.17.1. Physicians 15.17.2. Wholesalers 15.17.3. Physician Distributors 15.17.4. Government Entities 15.17.5. Public and Private Alliances 15.18. Rest of South America Human papillomavirus vaccine Market Forecast, by Valence 15.18.1. Bivalent 15.18.2. Quadrivalent and Nonavalent 15.19. Rest of South America Human papillomavirus vaccine Market Forecast, by Indication 15.19.1. Cervical Cancer 15.19.2. Anal Cancer 15.19.3. Vaginal Cancer 15.19.4. Penile Cancer 15.19.5. Vulvar Cancer 15.19.6. Oropharyngeal Cancer 15.19.7. Genital Warts 15.19.8. Others 15.20. Rest of South America Human papillomavirus vaccine Market Forecast, by Distribution Channel 15.20.1. Physicians 15.20.2. Wholesalers 15.20.3. Physician Distributors 15.20.4. Government Entities 15.20.5. Public and Private Alliances 15.21. South America Human papillomavirus vaccine Market Attractiveness Analysis 15.21.1. By Valence 15.21.2. By Indication 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. GlaxoSmithKline 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Astellas Pharma 16.3.3. CSL 16.3.4. Emergent BioSolutions 16.3.5. Johnson and Johnson 16.3.6. MedImmune 16.3.7. Merck 16.3.8. Pfizer 16.3.9. Sanofi Pasteur 16.3.10. Serum Institute 16.3.11. Bavarian Nordic 16.3.12. CSL Ltd. 16.3.13. Emergent Biosolutions, Inc. 16.3.14. F. Hoffmann-La Roche Ltd. 16.3.15. Gilead Sciences 16.3.16. Inovio Pharmaceuticals 16.3.17. Mitsubishi Tanabe Pharma Corporation 16.3.18. Novavax, Inc. 16.3.19. SELLAS Life Sciences Group, Inc. 17. Primary Key Insights